Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
BioRestorative Therapies, Inc. is a U.S.-based biotechnology company focused on the development of regenerative cell-based therapies. The company operates within the biotechnology and regenerative medicine industries, with an emphasis on adult stem cell therapeutics targeting musculoskeletal disorders and metabolic conditions. Its core programs are designed to address areas with significant unmet medical need, particularly chronic back pain and obesity-related diseases.
The company’s primary value proposition lies in its proprietary adult stem cell technology platforms, which are intended to promote tissue repair and functional restoration without the ethical concerns associated with embryonic stem cells. BioRestorative was founded in 2012 and has evolved from early-stage research into a clinical-stage company with investigational programs advancing through preclinical and early clinical development, supported by intellectual property filings and regulatory interactions.
Business Operations
BioRestorative’s operations are organized around two main therapeutic programs: the Disc/Spine Program, which targets degenerative disc disease using injectable cell-based therapies, and the ThermoStem Program, which focuses on metabolic disorders through brown adipose-derived stem cells. These programs represent the company’s primary research and development activities and potential future revenue drivers, subject to regulatory approval.
The company conducts its operations primarily in the United States and does not currently generate material commercial revenue, as its products remain in development. BioRestorative controls proprietary cell lines, preclinical data, and related intellectual property, and conducts research through internal capabilities and external research collaborators. Its metabolic disease platform is developed through its wholly owned subsidiary ThermoStem, Inc., which houses the brown fat stem cell assets.
Strategic Position & Investments
Strategically, BioRestorative aims to advance its lead spine and metabolic programs toward clinical validation, with a focus on achieving regulatory milestones that could enable partnerships or future commercialization. Growth initiatives center on progressing clinical trials, strengthening intellectual property protection, and expanding the therapeutic applications of its stem cell platforms.
The company has made targeted investments in research infrastructure and subsidiary development rather than large-scale acquisitions. ThermoStem, Inc. represents its most notable subsidiary investment and positions the company within the emerging intersection of regenerative medicine and metabolic disease treatment. BioRestorative is also involved in early-stage exploration of obesity and diabetes-related indications, though timelines and outcomes remain dependent on clinical and regulatory results.
Geographic Footprint
BioRestorative is headquartered in the United States, with its principal offices and research activities located in New York. Its operational footprint is primarily domestic, reflecting its current development-stage focus and regulatory engagement with U.S. authorities.
While the company does not maintain significant international operations, its therapeutic targets address global disease markets, and its intellectual property strategy is designed to support potential future international licensing or partnerships. International influence at present is limited to scientific collaboration and patent coverage rather than direct commercial activity.
Leadership & Governance
BioRestorative is led by its founder, who has guided the company since inception with a strategy centered on scientific differentiation and capital-efficient development. The leadership team combines executive management with scientific expertise to advance its regenerative medicine platforms.
Key executives include:
- Lance Alstodt – Chairman, President, and Chief Executive Officer
- Francesca Marini, PhD – Chief Scientific Officer
The leadership philosophy emphasizes disciplined capital management, protection of proprietary science, and methodical progression through regulatory pathways. Where public disclosures regarding additional executive roles are limited or inconsistent, data inconclusive based on available public sources.